在阿尔茨海默病中恢复粉样蛋白-β42和γ-分泌酶功能
Alberto J Espay1, Kariem Ezzat2, Kasper P Kepp3
1James J. and Joan A. Gardner Family Center for Parkinson's disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, OH 45219, USA.
Brain : a journal of neurology
|August 12, 2025
概括
阿尔茨海默氏病可能不是来自过多的粉样β 42 (Aβ42). 较低的Aβ42水平与更糟糕的结果相关,这表明Aβ42恢复可能是阿尔茨海默病的治疗策略.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 生物化学 生物化学
背景情况:
- 传统的阿尔茨海默氏病 (AD) 模型涉及增加的玛分泌酶活性和粉样β 42 (Aβ42) 的过度生产.
- 新出现的数据挑战了这一点,显示AD患者脑脊液Aβ42水平降低,特别是那些患有遗传突变或唐氏综合征的人.
研究的目的:
- 重新评估马分泌酶活性和Aβ42水平在阿尔茨海默病病理生理学中的作用.
- 探索恢复Aβ42水平作为治疗策略的潜力.
主要方法:
- 分析现有证据,将玛分泌酶功能,Aβ42水平和AD进展联系起来.
- 对基因研究 (APP,PSEN1,PSEN2突变) 和唐氏综合征的研究结果的审查.
- 检查抗粉胺疗法的效果和Aβ42.2.的潜在神经功能.
主要成果:
- 大约90%的致病性PSEN1突变会降低玛分泌酶活性和Aβ42的产生.
- 较低的玛分泌酶活性和可溶性Aβ42水平与早期痴呆发作,较差的认知能力和更快的进展相关.
- 在某些AD形式中,更高的可溶性Aβ42水平与保持认知和延迟痴呆症有关.
结论:
- 阿尔茨海默病的病理生理学可能涉及降低,而不是增加,玛分泌酶活性和Aβ42水平.
- 恢复Aβ42水平超过补偿值可能会带来疾病修饰的好处.
- 重新使用增加可溶性Aβ42的药物需要对减缓AD进展进行研究.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42 Aβ42在PSEN1上.氨基酸四十二诱导剂的诱导剂γ-秘密的秘密γ-分泌酶调节器更多相关视频
04:41Preparation of Oligomeric β-amyloid1-42 and Induction of Synaptic Plasticity Impairment on Hippocampal Slices
Published on: July 14, 2010
23.4K
09:31Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
Published on: March 7, 2019
10.8K
相关概念视频
01:22Alzheimer's Disease: Treatment
261
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
261
01:26Alzheimer's Disease: Overview
668
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
668